Intratumoral Injection of Autologous CD1c (BDCA-1)+ MyDC, Avelumab, and Ipilimumab Plus Systemic Nivolumab

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 29, 2018

Primary Completion Date

December 24, 2025

Study Completion Date

December 24, 2025

Conditions

Solid TumorMetastases to Soft Tissue

Interventions

DRUG

intratumoral injection of autologous CD1c (BDCA-1)+ myDC

intratumoral injections plus intravenous administration

DRUG

Intratumoral injection of ipilimumab and AS01b

DRUG

IV nivolumab

Nivolumab administered intravenously

Trial Locations (1)

RECRUITING

UZ Brussel, Jette

All Listed Sponsors

lead

Universitair Ziekenhuis Brussel

OTHER